Alpha 2.0
Login Register
» Authors » Takashi Owa

Takashi Owa

Explore the profile of Takashi Owa including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 27
Citations 1329
Followers 0
Related Specialties
Biochemistry
Oncology
Chemistry
Top 10 Co-Authors
Akira Yokoi
Kentaro Yoshimatsu
Yoichi Ozawa
Takeshi Nagasu
Naoko Hata Sugi
Mai Uesugi
Kentaro Iso
Yuji Yamamoto
Taisuke Uehara
Takeo Sasaki
Published In
Bioorg Med Chem Lett
Tanpakushitsu Kakusan Koso
J Med Chem
Cancer Res
Nat Chem Biol
Affiliations
Soon will be listed here.
Recent Articles
1.
A molecular glue RBM39-degrader induces synthetic lethality in cancer cells with homologous recombination repair deficiency
Kohsaka S, Yagishita S, Shirai Y, Matsuno Y, Ueno T, Kojima S, et al.
NPJ Precis Oncol . 2024 May; 8(1):117. PMID: 38789724
E7820 and Indisulam (E7070) are sulfonamide molecular glues that modulate RNA splicing by degrading the splicing factor RBM39 via ternary complex formation with the E3 ligase adaptor DCAF15. To identify...
2.
Ten-Gram-Scale Total Synthesis of the Anticancer Drug Candidate E7130 to Supply Clinical Trials
Kaburagi Y, Kira K, Yahata K, Iso K, Sato Y, Matsuura F, et al.
Org Lett . 2024 Jan; 26(14):2837-2842. PMID: 38252895
E7130 is a novel drug candidate with an exceedingly complex chemical structure of the halichondrin class, discovered by a total synthesis approach through joint research between the Kishi group at...
3.
NF-κB suppression synergizes with E7386, an inhibitor of CBP/β-catenin interaction, to block proliferation of patient-derived colon cancer spheroids
Kanda Y, Ohata H, Miyazaki T, Sakai H, Mori Y, Shiokawa D, et al.
Biochem Biophys Res Commun . 2021 Nov; 586:93-99. PMID: 34837838
Dysregulated activation of the WNT/β-catenin signaling pathway is essential for the initiation and development of various cancers. E7386, a small-molecule compound, attenuates WNT signaling by blocking the interaction between β-catenin...
4.
E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling
Yamada K, Hori Y, Inoue S, Yamamoto Y, Iso K, Kamiyama H, et al.
Cancer Res . 2021 Jan; 81(4):1052-1062. PMID: 33408116
The Wnt/β-catenin signaling pathway plays crucial roles in embryonic development and the development of multiple types of cancer, and its aberrant activation provides cancer cells with escape mechanisms from immune...
5.
Enhancement of Soft Tissue Sarcoma Response to Gemcitabine through Timed Administration of a Short-Acting Anti-Angiogenic Agent
Cheng J, Fuller J, Feldman R, Tap W, Owa T, Fuks Z, et al.
Cell Physiol Biochem . 2020 Jul; 54(4):707-718. PMID: 32722909
Background/aims: Despite enormous effort, anti-angiogenic drugs have not lived up to the promise of globally-enhancing anti-cancer therapies. Clinically, anti-angiogenic drugs have been used to persistently suppress vascular endothelial growth factor...
6.
β-Catenin/CBP inhibition alters epidermal growth factor receptor fucosylation status in oral squamous cell carcinoma
Chandler K, Alamoud K, Stahl V, Nguyen B, Kartha V, Bais M, et al.
Mol Omics . 2020 Mar; 16(3):195-209. PMID: 32203567
Epidermal growth factor receptor (EGFR) is a major driver of head and neck cancer, a devastating malignancy with a major sub-site in the oral cavity manifesting as oral squamous cell...
7.
A landmark in drug discovery based on complex natural product synthesis
Kawano S, Ito K, Yahata K, Kira K, Abe T, Akagi T, et al.
Sci Rep . 2019 Jun; 9(1):8656. PMID: 31209263
Despite their outstanding antitumour activity in mice, the limited supply from the natural sources has prevented drug discovery/development based on intact halichondrins. We achieved a total synthesis of C52-halichondrin-B amine...
8.
Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia
Wang E, Lu S, Pastore A, Chen X, Imig J, Chun-Wei Lee S, et al.
Cancer Cell . 2019 Feb; 35(3):369-384.e7. PMID: 30799057
RNA-binding proteins (RBPs) are essential modulators of transcription and translation frequently dysregulated in cancer. We systematically interrogated RBP dependencies in human cancers using a comprehensive CRISPR/Cas9 domain-focused screen targeting RNA-binding...
9.
Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome
Assi R, Kantarjian H, Kadia T, Pemmaraju N, Jabbour E, Jain N, et al.
Cancer . 2018 Apr; 124(13):2758-2765. PMID: 29660836
Background: Indisulam possesses anticancer properties through down-regulation of various cell-cycle checkpoint molecules, thereby blocking the phosphorylation of retinoblastoma protein and inducing p53 and p21. Indisulam exhibits synergy with nucleoside analogs...
10.
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
Italiano A, Soria J, Toulmonde M, Michot J, Lucchesi C, Varga A, et al.
Lancet Oncol . 2018 Apr; 19(5):649-659. PMID: 29650362
Background: Activating enhancer of zeste homolog 2 (EZH2) mutations or aberrations of the switch/sucrose non-fermentable (SWI/SNF) complex (eg, mutations or deletions of the subunits INI1 or SMARCA4) can lead to...